An interventional study of activated platelet-rich plasma and non-activated platelet-rich plasma in Temporomandibular Joint Disorders, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Cairo University · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Temporomandibular Joint Disorders by Cairo University — 8 open to participants now, 9 under way, none of them phase 3. Temporomandibular Joint Disorders · Cairo University.
Among the 30 studies in Temporomandibular Joint Disorders by Cairo University, this one is the 18th largest by planned enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2026, is one of 20 with no phase, and was the 30th registered.
593 studies on the registry are indexed under Temporomandibular Joint Disorders; 149 are open to participants now.
Browse Temporomandibular Joint Disorders studies →8 of the 30 studies in Temporomandibular Joint Disorders by Cairo University are open now, in 1 country. Recruiting first, the newest first:
Cairo University · Sites in Egypt
Ages 18–40
Cairo University · Sites in Egypt
Ages 18–50 · Healthy volunteers
Cairo University · Sites in Egypt
Ages 18+
Cairo University
Ages 18–40
Cairo University
Ages 16–50 · Healthy volunteers
By country, each count listing its studies:
Of the 76 Temporomandibular Joint Disorders studies recruiting now, 26 (34%) set no upper age limit and 46 (61%) stop at 75 or younger; 7 take children under 18; 23 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 3 started in 2026.
This study's planned enrollment of 20 is below the median of 45 across 417 interventional studies indexed under Temporomandibular Joint Disorders.
Median enrollment 29 across the 21 interventional studies, 200 across the 9 observational. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Cairo University is the lead sponsor of 4,967 studies on the registry; 1,474 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
2 of the studies in Temporomandibular Joint Disorders by Cairo University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07614932Cairo UniversityArthroscopic Lysis and Lavage With and Without Intra-articular Injection of Hyaluronic Acid in Patients With DDwoR in TMJ | 2027-01 |
| NCT07486609Cairo UniversityDiagnostic Study Accuracy of Jaw Motion Analyzer(JMA) Versus Research Diagnostic Criteria(RDC/TMD) and Magnetic Resonance Imaging(MRI) for Temporomandibular Disorders Among Patients With Chronic Orofacial Pain. | 2027-01-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 30 studies in Temporomandibular Joint Disorders by Cairo University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To compare the efficacy of retro discal injection of calcium gluconate-activated PRP versus non-activated PRP in adults with Anterior Disc Displacement with Reduction (ADDWR). Efficacy will be measured by the reduction of symptoms and the restoration of function, specifically targeting the normal Maximum Mouth Opening (MMO) range
To compare the efficacy of retro discal injection of calcium gluconate-activated PRP versus non-activated PRP in adults with Anterior Disc Displacement With Reduction (ADDWR). Efficacy will be measured by the reduction of symptoms and the restoration of function, specifically targeting the normal Maximum Mouth Opening (MMO) range.
Although laboratory evidence indicates that activation with Calcium Gluconate significantly enhances growth factor release compared to non-activated (resting) PRP, it remains clinically unproven whether this biochemical advantage translates into superior symptomatic relief and functional disc repositioning in TMJ patients. This trial seeks to determine if the additional step of activation yields a statistically significant clinical benefit over the simpler, non-activated technique.
By combining the biologically optimized injectate (Calcium Gluconate-Activated PRP) with the anatomically specific retrodiscal injection site-which is critical for addressing disc instability-this study aims to define a superior, evidence-based protocol. Determining the efficacy of this specific combination is essential for establishing a "gold standard" for non-surgical ADDWR management.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Systemic inflammatory arthritis (Rheumatoid arthritis, etc.).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intra-articular retro discal injection of autologous platelet-rich plasma (PRP)
Procedure: activated platelet-rich plasma
Intra-articular retrodiscal injection of autologous non-activated platelet-rich plasma
Procedure: non-activated platelet-rich plasma
Intra-articular retrodiscal injection of autologous platelet-rich plasma (PRP) activated with 0.5 milliliters of 10% sterile calcium gluconate per 5 milliliters of prepared PRP, administered as a single anatomical landmark-guided injection into the retrodiscal tissue.
Intra-articular retrodiscal injection of autologous non-activated platelet-rich plasma, prepared using identical double-centrifugation technique and administered using identical injection protocol and volume
Maximal Interincisal Opening (MIO)
measuring in millimeters using ruler
Time frame: 3 months
Pain Intensity
Visual Analog Scale (0-10)
Time frame: 3 months
Return of disc to normal position
using MRI imaging
Time frame: 3 months
Started Jul 2026 (actual). Primary completion is estimated for Oct 2026, 3 months after the start.
Of 244 non-industry interventional studies with no phase under Temporomandibular Joint Disorders, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 21. This study's planned 3 months is below that.
Counting every sponsor, half of 248 studies reached it within 11 months; a quarter within 5 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Temporomandibular Joint Disorders →